Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Inclusion Criteria: * Age ≥18 years. * Has pancreatic ductal adenocarcinoma * Has resectable disease at the time of diagnosis * Has not received any systemic therapy for pancreatic ductal adenocarcinoma * Has stage ≤ IIb disease at time of diagnosis and enrollment * Elevated tumor marker, CA (carbohydrate antigen) 19-9 \>200 * ECOG performance status 0 or 1 * Patient must have adequate organ function defined by the study-specified laboratory tests. * Must use acceptable form of birth control while on study. * Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria: Patients who have received any prior chemotherapy, radiotherapy or investigational agents for pancreatic cancer. * Patients who have received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137). * Has received prior therapy with FAK inhibitor. * Woman who are pregnant or breastfeeding. * Have received a live vaccine or live-attenuated vaccine within 30 days prior to study drug. * Is currently or has participated in another investigational study within 4 weeks prior to receiving study drug. * History or current use of immunosuppressive medications within 7 days prior to study medications. * Has a known additional malignancy that is progressing or has required active treatment within the past 2 years or that is expected to require active trea…